October 2025 – Talk Bio

Patient with Preexisting Immunity to AAV Vectors Granted Gene Therapy After Antibody-Depleting Agent Allowed Eligibility

8 hours ago talkbio0Tagged AAV antibodies, antibody-chopping drug, Clinical Trials, Eligibility Determination, gene therapy

gene therapy; AAV antibodies; ineligible; antibody-chopping drug; clinical trial; eligibility

AviadoBio Secures Option to Develop Rare Eye Disease Gene Therapy UGX-202 in $413 Million Deal with China’s UgeneX

13 hours ago talkbio0Tagged AviadoBio, China, gene therapy, Optogenetics, Retinitis Pigmentosa, UgeneX, UGX-202

AviadoBio; UgeneX; UGX-202; optogenetics; gene therapy; retinitis pigmentosa; China; $413 million deal

Ascenta Capital Closes $325 Million Inaugural Fund to Back Exceptional Development-Stage Biotechs

15 hours ago talkbio0Tagged Ascenta Capital, biotechs, Clinical Trials, Early-stage, Evan Rachlin, Funds, Investments, multi-medicine platforms, portfolio companies, venture capital

Ascenta Capital; biotech investment; venture capital; $325M fund; clinical trials; multi-medicine platforms; Evan Rachlin; Lorence Kim; early-stage biotechs; portfolio companies

Xspray’s Dasynoc Faces FDA Approval Delay Due to Contract Manufacturing Issues

15 hours ago talkbio0Tagged Acute lymphocytic leukemia, Complete Response Letter, contract manufacturer, Dasynoc, Drug Approval Process, manufacturing issues, manufacturing practice, Myeloid Leukemia, Chronic, United States Food and Drug Administration, Xspray Pharma

Dasynoc; Xspray Pharma; FDA; Complete Response Letter; manufacturing issues; good manufacturing practice; contract manufacturer; chronic myeloid leukemia; acute lymphoblastic leukemia; drug approval process

AviadoBio Secures Option to UgeneX’s UGX-202 Gene Therapy for Retinal Disease

15 hours ago talkbio0Tagged AviadoBio, Clinical Development, Dependovirus, gene therapy, Optogenetics, Retinal Diseases, Retinitis Pigmentosa, UGX-202

AviadoBio; UgeneX Therapeutics; UGX-202; retinitis pigmentosa; gene therapy; optogenetics; adeno-associated virus (AAV); exclusive option; retinal disease; clinical development

Ono’s BMS-Partnered Oral Gastric Cancer Drug Meets Primary Endpoint in Phase 2 Trial

15 hours ago talkbio0Tagged Advanced phase, Bristol Myers Squibb, EP4 antagonist, EP4 Antagonist ONO-4578, Episodic, HER2-negative, Malignant neoplasm of stomach, nivolumab, Opdivo, Pharmacotherapy, Phase 2, Progression-Free Survival

ONO-4578; EP4 antagonist; gastric cancer; Opdivo; nivolumab; Bristol-Myers Squibb; phase 2; progression-free survival; chemotherapy; HER2-negative; advanced; recurrent

Bristol Myers Squibb Enters In Vivo CAR-T Field with $1.5B Acquisition of Orbital Therapeutics

15 hours ago talkbio0Tagged Acquisition, Autoimmune Diseases, Automobiles, Cell Therapy, immune system reprogramming, in vivo, Myers Squibb, NUSAP1 gene, Obstetric Delivery, Orbital Therapeutics, OTX-201, RNA medicines, RNA, Circular, T-cell therapy

Bristol Myers Squibb; Orbital Therapeutics; in vivo CAR T-cell therapy; autoimmune diseases; RNA medicines; OTX-201; cell therapy; acquisition; LNP delivery; circular RNA; immune system reprogramming